Skip to main content

Table 6 ISS T-002: anti-Tat humoral and cellular immune response post-immunization

From: HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial

 

n

Percentage (95% CI a )

Odds ratio b (95% CI a )

Odds ratio p-value

Anti-Tat humoral responses

    

Vaccinees

155

79 (73–86)

  

Tat 7.5 μg, 3x

40

70 (56–84)

reference

 

Tat 7.5 μg, 5x

40

70 (56–84)

1.0 (0.5; 2.2)

1.0000

Tat 30 μg, 3x

38

92 (84–100)

5.0 (1.8; 13.9)

0.0021

Tat 30 μg, 5x

37

86 (75–97)

2.7 (1.1; 6.7)

0.0272

Anti-Tat cellular responses

    

Vaccinees

155

84 (79–90)

  

Tat 7.5 μg, 3x

40

80 (68–92)

reference

 

Tat 7.5 μg, 5x

40

88 (77–98)

1.7 (0.7; 4.4)

0.3253

Tat 30 μg, 3x

38

87 (76–98)

1.6 (0.6; 4.2)

0.2900

Tat 30 μg, 5x

37

84 (72–96)

1.3 (0.5; 3.2)

0.5758

Comparison among groups

   

0.6697c

  1. n indicates the number of individuals evaluable for each parameter.
  2. aConfidence interval; bLogistic regression model; cMantel-Haenszel Chi-Square test.